Single oral immunotherapy desensitizes patients to multiple foods healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
SAN ANTONIO — Remibrutinib displayed sustained efficacy for chronic spontaneous urticaria with a favorable safety profile over 52 weeks, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.“Treating these patients has a huge, huge impact on the patient’s well-being and quality of life,” Warner W. Carr, MD, FACP, FACAAI,